Recruiting Fabry Disease Studies in Cincinnati
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents with Fabry Disease....
A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease
This Phase 1/2 first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15421 in patients with FD....
About Fabry Disease Clinical Trials in Cincinnati
Fabry disease is a rare genetic disorder caused by deficiency of the enzyme alpha-galactosidase A, leading to accumulation of a fatty substance in cells. It can affect the heart, kidneys, and nervous system. Treatment includes enzyme replacement therapy and chaperone therapy.
There are currently 2 fabry disease clinical trials recruiting participants in Cincinnati, OHIO. These studies are seeking a combined 40 participants. Research is being sponsored by Chiesi Farmaceutici S.p.A., GC Biopharma Corp. Clinical trial participation is free and participants receive study-related medical care at no cost.
Fabry Disease Clinical Trials in Cincinnati — FAQ
Are there fabry disease clinical trials in Cincinnati?
Yes, there are 2 fabry disease clinical trials currently recruiting in Cincinnati, OHIO. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Cincinnati?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Cincinnati research site will contact you about next steps.
Are clinical trials in Cincinnati free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Cincinnati studies also compensate for your time and travel.
What fabry disease treatments are being tested?
The 2 active trials in Cincinnati are testing new therapies including novel drugs, biologics, and treatment approaches for fabry disease.
Data updated March 2, 2026 from ClinicalTrials.gov